No abstract

No abstract

No abstract

BACKGROUND: A high prevalence of metabolic syndrome in persons with serious mental illness, particularly in patients with schizophrenia, is noted. In addition, psychotropic agents, including some antipsychotic medications, are associated with substantial weight gain and pose an increased risk of metabolic syndrome. METHODS: This cross-sectional case–control study is aimed at establishing the prevalence of diabetes mellitus, obesity, and hyperlipidemia in patients with schizophrenia on antipsychotic medication and to see whether clozapine was associated with a higher prevalence of these disorders as compared to other antipsychotic drugs. RESULTS: The body mass index, diabetes mellitus, levels of high-density lipoprotein cholesterol, and hypertriglyceridemia did not differ significantly between both the groups. CONCLUSION: Thus, the prevalence of clozapine-induced metabolic syndrome is not higher than other antipsychotics and not as common as reported in the Western literature.